Drug intelligence / Profile preview

Amnioband

Development stage: Unknown
Lead developer: MTF Biologics
Modality: Cell Therapies
Administration: Topical

Overview

Amnioband is a biological wound covering developed by MTF Biologics. It is an aseptically processed, dehydrated human amnion/chorion allograft (dHACA) derived from the placental tissues of healthy donors. Composed of both amnion and chorion layers, it serves as a structural scaffold rich in extracellular matrix proteins, cytokines, and growth factors. It is primarily indicated for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), where it facilitates tissue remodeling and wound closure. Clinical studies have demonstrated high rates of full wound closure in patients treated with Amnioband compared to standard conservative therapy.

Brand names: AmnioBandAmnioBand Membrane
Other names: dehydrated human amnion/chorion allograftdHACA

Beyond the preview

Go deeper on Amnioband.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amnioband.

Explore the full profile